This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the PD-L1 ADC mechanism with a specific focus on SGN-PDL1V and MT-6402

Ticker(s): SGEN

Who's the expert?

Institution: PA Cancer Specialist and Research Institute

  • Oncologist in private practice with 30+ years of experience.
  • Areas of interest include solid tumors such as lung, breast, and colon as well as hematological disorders, anemia, lymphoma, and leukemia.
  • Practice has approximately 20+ open clinical trials from Phase I to registry.

Interview Goal
This conversation will focus on the PD-L1 ADC mechanism and publicly available data for SGN-PDL1V (Seagen's investigational vedotin ADC directed to the T cell checkpoint ligand, PD-(L)1) and MT-6402 (a third generation engineered toxin body currently in development by Molecular Templates).

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.